Back to Search
Start Over
Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as biomarkers of acute kidney injury after ST-segment elevation myocardial infarction treated by percutaneous coronary intervention
- Source :
- Archives of cardiovascular diseases, Archives of cardiovascular diseases, Elsevier/French Society of Cardiology, 2019, 112 (3), pp.180-186. ⟨10.1016/j.acvd.2018.11.006⟩
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
-
Abstract
- Summary Background Two biomarkers of early acute kidney injury − plasmatic neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C − are not used in routine clinical practice in patients with ST-segment elevation myocardial infarction (STEMI) treated by percutaneous coronary intervention (PCI) because of a lack of supporting data. Aims To evaluate the predictive value of NGAL and cystatin C regarding the incidence of contrast-induced acute kidney injury (CI-AKI) and clinical outcomes after STEMI in patients treated by primary PCI. Methods Plasmatic NGAL and cystatin C were measured on admission, before any contrast exposure, in 701 unselected patients with STEMI. Associations between biomarker concentrations and incidence of CI-AKI (assessed at 48 h), haemodialysis requirement at 1 year and all-cause mortality at 1 year were assessed by logistic regression analyses and receiver operating characteristic area under the curve analysis (c-statistic). Discrimination performance comparison was performed using the DeLong test. Results NGAL and cystatin C had mild discrimination regarding CI-AKI, with c-statistics of 0.60 (P = 0.001) and 0.60 (P = 0.002), respectively. Combining NGAL and cystatin C did not improve their discrimination (c-statistic 0.61; P = 0.001). There was no significant difference in discrimination between NGAL, cystatin C and baseline creatinine (P = 0.57). Regression analyses showed no independent association between NGAL and CI-AKI, haemodialysis or 1-year mortality. Similarly, cystatin C was not associated with these clinical outcomes. Conclusions In this cohort of patients with STEMI treated by primary PCI, plasmatic NGAL and cystatin C did not provide additional value regarding CI-AKI prediction compared with known risk factors such as baseline creatinine.
- Subjects :
- Male
[SDV]Life Sciences [q-bio]
medicine.medical_treatment
Contrast Media
030204 cardiovascular system & hematology
urologic and male genital diseases
Gastroenterology
chemistry.chemical_compound
0302 clinical medicine
Risk Factors
Prospective Studies
030212 general & internal medicine
Myocardial infarction
Primary PCI
Aged, 80 and over
biology
Incidence
Acute kidney injury
General Medicine
Middle Aged
female genital diseases and pregnancy complications
Treatment Outcome
Creatinine
Biomarker (medicine)
Female
Cystatin
Cardiology and Cardiovascular Medicine
Paris
medicine.medical_specialty
STEMI
03 medical and health sciences
Percutaneous Coronary Intervention
Lipocalin-2
[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Predictive Value of Tests
Internal medicine
medicine
Humans
Contrast volume
Cystatin C
Aged
business.industry
Percutaneous coronary intervention
medicine.disease
chemistry
Conventional PCI
biology.protein
ST Elevation Myocardial Infarction
business
Biomarkers
Subjects
Details
- ISSN :
- 18752136
- Volume :
- 112
- Database :
- OpenAIRE
- Journal :
- Archives of Cardiovascular Diseases
- Accession number :
- edsair.doi.dedup.....88bf0633ba29156f24b1fff7a895e068